Claficapavir (Synonyms: A1752) |
| Katalog-Nr.GC66467 |
Claficapavir (A1752) ist ein spezifischer Inhibitor des Nukleokapsidproteins (NC) mit einem IC50 von etwa 1 μM. Claficapavir bindet stark an HIV-1 NC (Kd = 20 nM), hemmt dadurch die Chaperoneigenschaften von NC und fÜhrt zu einer guten antiviralen AktivitÄt gegen HIV-1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2055732-24-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC50 around 1 μM. Claficapavir strongly binds the HIV-1 NC (Kd=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1[1].
Claficapavir binds directly to HIV-1 NC, thereby inhibiting specific chaperone functions of NC including Psi RNA dimerization and complementary trans-activation response element (cTAR) DNA destabilization, and it also disrupts the proper Gag processing[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *